Biologic and advanced therapy registers in rheumatoid arthritis

The introduction of biologic disease-modifying anti-rheumatic drugs (bDMARDs) has improved outcomes in patients with rheumatoid arthritis (RA), although there are concerns about the long-term safety of these drugs, especially lymphoma and serious infection. Biologic registers have been established to investigate the long-term safety and effectiveness of biologic drugs in RA. To date, publications from biologic registers have focused mainly on anti-tumour necrosis factor (TNF) therapy, although reports of outcomes after other biologic classes are increasing.
Source: Medicine - Category: Internal Medicine Authors: Tags: Spondyloarthropathies Source Type: research